Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/GILD
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Gilead Sciences, Inc. (GILD) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $146.64, down 2.88% on the day, with a bullish technical outlook from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026's loss narrower than expected, and maintains a high gross profit margin of 79.59%. Recent FDA approvals for Bixlenvo and Trodelvy expansion highlight growth initiatives, though net income turned negative in 2026. Cash flow from operations remains robust at $10.02B for 2025, supporting dividend payments.
The stock offers a balanced risk-reward profile, with analyst consensus favoring a buy rating and a $149.50 price target implying modest upside. Key opportunities include HIV franchise strength and oncology pipeline advances, while risks involve patent expirations, high debt levels, and profitability volatility. Institutional interest is mixed, with recent filings showing both new acquisitions and reductions.
Read full analysis

Key Stats

  • Market Cap
    $181.83B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    -
  • Enterprise Value
    $204.89B
  • Div Yield
    2.24%
  • Trading Activity
    -
$145.72
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Most Recent News

Content is generated by Aura AI

Bitmine nears 5% ETH supply goal with $15.7B crypto holdings, driving strong Q3 gains and staking over 5M ETH.

Bitmine Immersion Technologies has accumulated 4.9% of the total Ethereum supply, holding $15.7 billion in crypto assets including 5.93 million ETH. The company has achieved 97% of its goal to acquire 5% of all ETH in just 15 months, contributing to ...

Market News
4 hours ago
PRNewsWire
Bullish
news icon
Bitmine nears 5% ETH supply goal with $15.7B crypto holdings, driving strong Q3 gains and staking over 5M ETH.

US sanctions Xinbi Guarantee, a Chinese-linked scam platform laundering $52M in crypto from Americans

The US Attorney for the District of Columbia announced sanctions against Xinbi Guarantee, an online platform used by Chinese cybercriminals to facilitate scams targeting Americans, including fraudulent cryptocurrency investments. Authorities restrain...

Market News
4 hours ago
Fox Business
Bearish
news icon
US sanctions Xinbi Guarantee, a Chinese-linked scam platform laundering $52M in crypto from Americans

Jim Cramer favors Morgan Stanley over fintechs, praising its steady growth and $10T client assets milestone.

Jim Cramer expressed skepticism about the wave of new fintech and blockchain IPOs, describing many as similar and hard to differentiate. Instead, he highlighted Morgan Stanley as a strong, quietly executing incumbent that recently surpassed $10 trill...

Market News
4 hours ago
24/7 Wall Street
Bullish
news icon
Jim Cramer favors Morgan Stanley over fintechs, praising its steady growth and $10T client assets milestone.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $181.83B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    -
  • Enterprise Value
    $204.89B
  • Div Yield
    2.24%
  • Trading Activity
    -
$145.72
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!